Kenneth D Aldape

发表

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Walter J Curran, Deborah T Blumenthal, Mark R Gilbert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation.

Luo Wang, Randa El-Zein, Sujit S Prabhu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.

Jing Xu, Satoru Kyo, Hong Jiang, 2005, Journal of the National Cancer Institute.

RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

Robert Jeraj, Maria Werner-Wasik, Deborah T Blumenthal, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics

Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, K. Aldape, 2014, Modern Pathology.

Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.

Jane Fridlyand, Justin Chen, Bruno M Costa, 2010, Cancer research.

The Mitosis-Specific Antibody Anti-Phosphohistone-H3 (PHH3) Facilitates Rapid Reliable Grading of Meningiomas According to WHO 2000 Criteria

Teresa Ribalta, K. Aldape, G. Fuller, 2004, The American journal of surgical pathology.

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Raymond Sawaya, Allan H Friedman, Mark R Gilbert, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.

Ken Chen, John N Weinstein, Lynda Chin, 2013, Genes & development.

FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells.

Raymond Sawaya, Suyun Huang, K. Aldape, 2006, Cancer research.

Molecular epidemiology of glioblastoma.

Margaret Wrensch, K. Aldape, M. Wrensch, 2003, Cancer journal.

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.

Howard Colman, B Nebiyou Bekele, Mark R Gilbert, 2010, Neuro-oncology.

The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.

Ganesh Rao, Howard Colman, Khalida Wani, 2011, Genes & development.

Clinical actionability enhanced through deep targeted sequencing of solid tumors.

Yuan Qi, Ken Chen, Zechen Chong, 2015, Clinical chemistry.

Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.

Mitchel S Berger, Raj K Puri, Susan M. Chang, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using the molecular classification of glioblastoma to inform personalized treatment

K. Aldape, A. Olar, Kenneth D Aldape, 2014, The Journal of pathology.

Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.

Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, K. Aldape, 2013, The Journal of molecular diagnostics : JMD.

Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.

Arie Perry, Rakesh Nagarajan, Mark A Watson, 2007, Cancer research.

Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.

Hiroyuki Nishimori, James P Basilion, Wadih Arap, 2011, The Journal of clinical investigation.

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

Rebecca A Betensky, Matija Snuderl, David N Louis, 2011, Cancer cell.

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Zhaoshi Jiang, Somasekar Seshagiri, Franklin Peale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance

Caterina Giannini, Alfred Furth, Karla Ballman, 2004, Journal of neuropathology and experimental neurology.

Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression.

Carol L Nilsson, Charles A Conrad, K. Aldape, 2007, Journal of proteome research.

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

Timothy F Cloughesy, Mark R Gilbert, Patrick Y Wen, 2008, Neuro-oncology.

GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity.

Gelareh Zadeh, Shahrzad Jalali, K. Aldape, 2014, Neuro-oncology.

Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class

Christina Appin, David A Gutman, Daniel J Brat, 2013, Clinical Cancer Research.

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

Carmen Behrens, Ignacio I Wistuba, K. Aldape, 2009, Clinical Cancer Research.